TNF and pouchitis: A larger systematic review and meta-analysis including 15 studies with 311 patients with chronic antibiotic refractory pouchitis, reported pooled rates of clinical improvement as 71.4%, 58.2%, 47.9% and those of clinical remission as 65.7%, 31%, 47.4% with anti-tumor necrosis factor therapy (infliximab and adalimumab) and vedolizumab, respectively.31